Is Proton Beam Radiotherapy Worthwhile in the Management of Angiosarcoma of the Scalp?


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 23 01 2020
revised: 06 02 2020
accepted: 13 02 2020
entrez: 6 3 2020
pubmed: 7 3 2020
medline: 16 4 2020
Statut: ppublish

Résumé

In inoperable patients, the management of angiosarcoma of the scalp is challenging. Due to intrinsic, dosimetric and radiobiological properties, proton beam radiotherapy may be an effective and safe option to offer to these difficult-to-cure patients. Here, we report a case of angiosarcoma of the scalp treated successfully with proton beam radiotherapy. Angiosarcoma is a rare malignancy concerning around 2% of soft-tissue sarcomas and 5% of cutaneous soft-tissue sarcomas. Cutaneous angiosarcomas can occur in any part of the body, but the head and neck region is a common primary site and the scalp is a frequent site in elderly patients.

Identifiants

pubmed: 32132069
pii: 40/3/1645
doi: 10.21873/anticanres.14114
doi:

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1645-1649

Informations de copyright

Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Viviana Vitolo (V)

National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy.

Amelia Barcellini (A)

National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy Amelia.Barcellini@cnao.it.

Alfredo Mirandola (A)

National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy.

Angelica Facoetti (A)

National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy.

Alberto Iannalfi (A)

National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy.

Barbara Vischioni (B)

National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy.

Maria Rosaria Fiore (MR)

National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy.

Silvia Brugnatelli (S)

Department of Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Simona Secondino (S)

Department of Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Sara Ronchi (S)

National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy.

Maria Bonora (M)

National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy.

Lorenzo Preda (L)

National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy.
Department of Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Department of Clinical-Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.

Francesca Valvo (F)

National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH